Happy Thursday. Medicine had one of those weeks where the press releases sounded tidy and the politics underneath looked anything but. A kidney drug got accelerated approval with a price tag that could buy a house. A pancreatic cancer medicine entered Europe’s fast lane, while patients still need the road after the regulator opens the gate. Europe is trying to simplify device rules without breaking trust in diagnostics. Insurers are pushing premiums higher. Fake condoms crossed borders. PFAS met a soft regulatory hand. Big Pharma went shopping in China again.
The theme is not subtle. A system can approve the drug, review the trial, certify the test, publish the guidance and still fail the patient. That is why this issue is about proof and the route beyond it. Evidence matters. But evidence sitting behind a price, a missing diagnostic, a weak regulator, a broken insurance market or a fake product is not access. It is paperwork with better branding
- The $425,000 Kidney Promise. FDA approved Trutakna for primary IgA nephropathy under accelerated approval. The proteinuria signal is real. So is the price.
- Pancreatic Cancer Got the Fast Lane. Patients Still Need the Road. EMA has started a phased review of daraxonrasib. Regulatory speed is welcome. System speed is the harder test.
- Europe Keeps Calling the Test a Detail. It Is the Door. MDR and IVDR simplification may sound like Brussels machinery. For personalised medicine, it decides whether patients can actually be tested.
- The Premium Is the New Waiting Room. ACA Marketplace insurers are proposing a 14% median premium increase for 2027. Access can fail before the patient ever sees a clinician.
- Fake Condoms, Real Consequences. OLAF traced more than 200,000 counterfeit condoms moving through Europe. Prevention collapses when the product at the point of use is fake.
- Forever Chemicals Got a Soft Touch. FDA rejected a petition for enforceable PFAS limits in food. Upstream prevention is hard to take seriously when the upstream rule has no hard edge.
- China Is Not Just the Market. It Is the Pipeline. AstraZeneca is licensing a Chinese experimental COPD drug in a deal worth up to $1.9 billion. The innovation map is moving.
- Vertex Bought the Rare-Disease Doorway. The company’s $10 billion Crinetics deal is not just an acquisition. It is a move deeper into specialised patient pathways.
- The Obesity Pill Worked. The Body Objected. Kailera’s oral GLP-1 hit late-stage goals in China, but nausea and vomiting turned efficacy into a real-world access question.
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
The $425,000 Kidney Promise
FDA has approved Vera Therapeutics’ Trutakna for adults with primary IgA nephropathy at risk of disease progression. The approval is accelerated, based on reduction in proteinuria rather than completed hard kidney-function outcomes. FDA reported an average 46% reduction in proteinuria at nine months compared with placebo. Reuters reported that Vera priced the drug at about $425,000 per year, with additional kidney-function data expected in Q3 2026. (FDA and Reuters)
This is the politics of accelerated approval in one price tag. Patients with progressive kidney disease need earlier options, and proteinuria is not a trivial signal. But when the outcome evidence is still maturing and the annual cost is nearly half a million dollars, the payer is not just buying a drug. It is buying uncertainty. Faster approval can be justified. Faster proof, clear follow-up obligations and a serious access plan are what stop hope from becoming a very expensive promise.
Pancreatic Cancer Got the Fast Lane. Patients Still Need the Road.
EMA has started a phased review of daraxonrasib for previously treated metastatic pancreatic cancer, allowing its human medicines committee to assess quality, non-clinical and clinical data in stages before a full marketing-authorisation application is submitted. EMA says the medicine has been recognised as a high priority under its Cancer Medicines Pathfinder project because of the potential to address high unmet medical need. Revolution Medicines says the review is based on the pivotal Phase 3 RASolute 302 trial. (EMA and Revolution Medicines.)
This is exactly where speed belongs. Pancreatic cancer does not give patients generous timelines, and a slow system becomes part of the harm. But Europe should not confuse a faster file with faster care. If the medicine moves forward, patients will still need diagnosis, molecular profiling, specialist referral, reimbursement and oncology capacity that can move at the same pace. The regulator can open the fast lane. Health systems still have to stop building potholes after the gate.
Europe Keeps Calling the Test a Detail. It Is the Door.
The European Commission’s proposal to simplify MDR and IVDR rules aims to reduce burden for medical devices and in vitro diagnostics while keeping patient safety and performance standards in place. That sounds technical until the diagnostic is the difference between receiving the right treatment and missing the pathway entirely. WHO says around 70% of healthcare decisions are based on diagnostic test results, while only 3% to 5% of health budgets go to diagnostic services. MedTech Europe says IVD results influence up to 70% of clinical decisions while accounting for less than 2% of total healthcare expenditure. (European Commission, WHO and MedTech Europe.)
For personalised medicine, diagnostics are not a supporting actor. They are the door. Europe can approve sophisticated cancer medicines and still block access if the test is delayed, unaffordable, uncertified, unreimbursed or unavailable outside major centres. Better regulation should not mean weaker standards. It should mean rules that protect patients without quietly removing tests from the clinic. No test, no target. No target, no treatment. No diagnostic access, no personalised medicine.
The Premium Is the New Waiting Room
ACA Marketplace insurers are proposing a 14% median premium increase for 2027, according to KFF’s analysis of preliminary filings from 77 insurers across 16 states and Washington, DC. Reuters reported that the proposed increase would be the second-highest since 2018, following the expiration of enhanced pandemic-era subsidies. KFF says premiums for participating insurers could rise by more than one-third between 2025 and 2027 if the increases are approved. (KFF and Reuters)
This is not a side issue for personalised medicine. It is the front door to everything else. A patient priced out of coverage is not arriving early for screening, diagnostics, risk stratification, referral or treatment. Health policy loves to talk about innovation once the patient enters the system. Insurance design decides whether they get that far. The waiting room is no longer only in the hospital. Sometimes it arrives as a premium notice.
Fake Condoms, Real Consequences
The European Anti-Fraud Office has traced a cross-border route used to distribute more than 200,000 counterfeit condoms in Europe. OLAF said the fake products were sold using the name and logo of a well-known brand, moved through Romania, Serbia and Spain, and were falsely declared as toys. The agency warned that the products did not meet EU quality requirements, including checks for microbial contamination, biocompatibility, leaks, dimensions, shelf life and stability. (OLAF)
This is what public health looks like when it leaves the conference room and reaches the point of use. A counterfeit condom is not just an intellectual-property problem. It is a pregnancy risk, an STI risk and a reminder that prevention depends on boring things done well: customs checks, supply-chain integrity, product testing and enforcement. Europe can talk all day about AI, genomics and precision oncology. If the basic device is fake, the policy has already failed upstream.
Forever Chemicals Got a Soft Touch
The FDA rejected a petition asking it to set enforceable PFAS limits in food, according to reporting by The Guardian. The petition sought legal limits for “forever chemicals” in foods including seafood and milk. FDA’s own guidance describes action levels as a risk-management tool but says they do not establish a permissible level of contamination, which means they are not the same as binding tolerances that make products unlawful above a defined threshold. (The Guardian and FDA guidance.)
This is prevention politics wearing soft gloves. Regulators can look active while choosing tools that leave the harder fight for later. But exposure does not care whether the government prefers a flexible framework. If food is a meaningful route for chemical exposure, public health has to ask why contamination is regulated firmly in some places and politely in others. Personalised medicine cannot only be about treating damage more precisely. It also has to mean stopping avoidable risk before the clinic inherits it.
China Is Not Just the Market. It Is the Pipeline.
AstraZeneca has secured ex-China rights to Sino Biopharmaceutical’s experimental COPD drug TQC3721. The deal includes $200 million upfront and potential payments of up to $1.9 billion linked to development, regulatory and sales milestones. Reuters reported that TQC3721 showed improvements in lung function and symptoms in a Phase II trial in China, while Sino Biopharmaceutical said AstraZeneca gains the right to develop, manufacture and commercialise the medicine outside China. (Reuters)
This is the China story without the old script. China is no longer just where multinational companies sell, manufacture or run trials. It is becoming a place where assets originate and global companies come to license them. That changes the politics of biopharma power. The map is no longer Western discovery, global development, emerging-market access. The pipeline is becoming multipolar. Europe should notice before it becomes the continent that debates competitiveness while everyone else signs the deals.
Vertex Bought the Rare-Disease Doorway
Vertex has agreed to acquire Crinetics Pharmaceuticals for about $10 billion, offering $85 per share in cash. Reuters calculated that the offer represents a 102% premium to Crinetics’ previous close. The deal brings Vertex Palsonify, a once-daily oral therapy approved for adult acromegaly, and atumelnant, a late-stage candidate for congenital adrenal hyperplasia. Vertex said Crinetics could add a potential $5 billion peak-sales opportunity and expand the company into endocrinology as a fifth therapeutic area. (Vertex and Reuters)
This is not only a company buying another company. It is a company buying a doorway into specialised disease management. Rare endocrine disorders need patient identification, specialist networks, long-term monitoring and payer confidence. The product matters, but the pathway is the moat. Big Pharma is no longer just buying molecules. It is buying access architecture.
The Obesity Pill Worked. The Body Objected.
Kailera Therapeutics said its oral GLP-1 drug HRS-7535 met its primary goals in late-stage China trials, with weight loss of up to 10.9% at week 44 and 11.1% at week 50. Reuters reported that nausea affected about 70% of treated patients and vomiting affected more than 65%, compared with 16.2% and 4.5% on placebo. Kailera shares fell after the data, despite the efficacy result. (Reuters)
This is the obesity-drug race growing up. Efficacy is no longer enough to win the room. The real world cares about nausea, vomiting, adherence, persistence, price, supply and whether patients can stay on treatment long enough for the benefit to matter. The endpoint said the pill worked. The body asked for a negotiation.
The Mid-July Watch
| 8–17 July, Geneva: |
| WHO’s Pandemic Agreement negotiations continue. The fight is over pathogen samples, benefit-sharing and who controls access when the next outbreak hits. (WHO) |
| 9–10 July, Dublin: |
| Ireland hosts the informal EU Competitiveness Council. Biotech, industrial policy and Europe’s ability to scale innovation are firmly on the table. (Irish Presidency) |
| 7–15 July, New York: |
| The UN High-level Political Forum reviews progress on the Sustainable Development Goals. Watch whether health is treated as a budget line or as the result of inequality, infrastructure and political choices. (United Nations) |
| 11 July, Global: |
| World Population Day puts reproductive health, demographic change and the future health workforce back on the agenda. (UNFPA) |
| 22 July, Americas and online: |
| PAHO looks at neonatal sepsis and antimicrobial resistance. The real question is whether newborns can get the diagnostics, antibiotics and care they need before infection becomes irreversible. (PAHO) |
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.
International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium
This email was sent to jayasinghtec29@gmail.com. You are receiving this email because you are part of the IPM Alliance network or have engaged with our activities, briefings, events, or policy work.
